Antibiotic Saving Effect of Combination Therapy Through Synergistic Interactions Between Well-characterized Chito-oligosaccharides and Commercial Antifungals Against Medically Relevant Yeasts

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2020 Jan 1

PMID 31891619

Citations 9

Authors

Monica Ganan

Silje B Lorentzen

Berit B Aam

Vincent G H Eijsink

Peter Gaustad

Morten Sorlie

Affiliations

Soon will be listed here.

Abstract

Combination therapies can be a help to overcome resistance to current antifungals in humans. The combined activity of commercial antifungals and soluble and well-defined low molecular weight chitosan with average degrees of polymerization (DPn) of 17-62 (abbreviated C17 -C62) and fraction of acetylation (FA) of 0.15 against medically relevant yeast strains was studied. The minimal inhibitory concentration (MIC) of C32 varied greatly among strains, ranging from > 5000 μg mL-1 (Candida albicans and C. glabrata) to < 4.9 (C. tropicalis). A synergistic effect was observed between C32 and the different antifungals tested for most of the strains. Testing of several CHOS preparations indicated that the highest synergistic effects are obtained for fractions with a DPn in the 30-50 range. Pre-exposure to C32 enhanced the antifungal effect of fluconazole and amphotericin B. A concentration-dependent post-antifungal effect conserved even 24 h after C32 removal was observed. The combination of C32 and commercial antifungals together or as part of a sequential therapy opens new therapeutic perspectives for treating yeast infections in humans.

Citing Articles

Anti-COVID-19 Credentials of Chitosan Composites and Derivatives: Future Scope?.

Gopal J, Muthu M, Pushparaj S, Sivanesan I Antibiotics (Basel). 2023; 12(4).

PMID: 37107027 PMC: 10135369. DOI: 10.3390/antibiotics12040665.

Synergistic Effect of Polysaccharides from Chamomile Tea with Nitazoxanide Increases Treatment Efficacy against .

Sabatke B, Chaves P, Cordeiro L, Ramirez M Life (Basel). 2022; 12(12).

PMID: 36556456 PMC: 9785495. DOI: 10.3390/life12122091.

The Chitosan-Based System with Extract for the Local Treatment of Vaginal Infections.

Chanaj-Kaczmarek J, Rosiak N, Szymanowska D, Rajewski M, Wender-Ozegowska E, Cielecka-Piontek J Pharmaceutics. 2022; 14(4).

PMID: 35456574 PMC: 9028937. DOI: 10.3390/pharmaceutics14040740.

Synergistic Antifungal Activity of Chito-Oligosaccharides and Commercial Antifungals on Biofilms of Clinical Isolates.

Ganan M, Lorentzen S, Gaustad P, Sorlie M J Fungi (Basel). 2021; 7(9).

PMID: 34575756 PMC: 8464920. DOI: 10.3390/jof7090718.

Preparation and Antimicrobial Activity of Chitosan and Its Derivatives: A Concise Review.

Confederat L, Tuchilus C, Dragan M, Shaat M, Dragostin O Molecules. 2021; 26(12).

PMID: 34204251 PMC: 8233993. DOI: 10.3390/molecules26123694.

References

Rabea E, Badawy M, Stevens C, Smagghe G, Steurbaut W . Chitosan as antimicrobial agent: applications and mode of action. Biomacromolecules. 2003; 4(6):1457-65. DOI: 10.1021/bm034130m. View

Manavathu E, Ramesh M, Baskaran I, Ganesan L, Chandrasekar P . A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans. J Antimicrob Chemother. 2004; 53(2):386-9. DOI: 10.1093/jac/dkh066. View

Palmeira-de-Oliveira A, Ribeiro M, Palmeira-de-Oliveira R, Gaspar C, Costa-de-Oliveira S, Correia I . Anti-Candida activity of a chitosan hydrogel: mechanism of action and cytotoxicity profile. Gynecol Obstet Invest. 2010; 70(4):322-7. DOI: 10.1159/000314023. View

Cortez K, Roilides E, Quiroz-Telles F, Meletiadis J, Antachopoulos C, Knudsen T . Infections caused by Scedosporium spp. Clin Microbiol Rev. 2008; 21(1):157-97. PMC: 2223844. DOI: 10.1128/CMR.00039-07. View

Park Y, Kim M, Park S, Cheong H, Jang M, Nah J . Investigation of the antifungal activity and mechanism of action of LMWS-chitosan. J Microbiol Biotechnol. 2008; 18(10):1729-34. View

MacKenzie F, Gould I . The post-antibiotic effect. J Antimicrob Chemother. 1993; 32(4):519-37. DOI: 10.1093/jac/32.4.519. View

Beer K, Farnon E, Jain S, Jamerson C, Lineberger S, Miller J . Multidrug-Resistant Aspergillus fumigatus Carrying Mutations Linked to Environmental Fungicide Exposure - Three States, 2010-2017. MMWR Morb Mortal Wkly Rep. 2018; 67(38):1064-1067. PMC: 6188124. DOI: 10.15585/mmwr.mm6738a5. View

El-Sharif A, Hussain M . Chitosan-EDTA new combination is a promising candidate for treatment of bacterial and fungal infections. Curr Microbiol. 2010; 62(3):739-45. DOI: 10.1007/s00284-010-9777-0. View

Lamb D, Kelly D, Schunck W, Shyadehi A, Akhtar M, Lowe D . The mutation T315A in Candida albicans sterol 14alpha-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity. J Biol Chem. 1997; 272(9):5682-8. DOI: 10.1074/jbc.272.9.5682. View

10.

Sorbotten A, Horn S, Eijsink V, Varum K . Degradation of chitosans with chitinase B from Serratia marcescens. Production of chito-oligosaccharides and insight into enzyme processivity. FEBS J. 2005; 272(2):538-49. DOI: 10.1111/j.1742-4658.2004.04495.x. View

11.

Verweij P, Chowdhary A, Melchers W, Meis J . Azole Resistance in Aspergillus fumigatus: Can We Retain the Clinical Use of Mold-Active Antifungal Azoles?. Clin Infect Dis. 2015; 62(3):362-8. PMC: 4706635. DOI: 10.1093/cid/civ885. View

12.

Calamari S, Bojanich M, Barembaum S, Berdicevski N, Azcurra A . Antifungal and post-antifungal effects of chlorhexidine, fluconazole, chitosan and its combinations on Candida albicans. Med Oral Patol Oral Cir Bucal. 2010; 16(1):e23-8. DOI: 10.4317/medoral.16.e23. View

13.

Ben-Ami R . Treatment of Invasive Candidiasis: A Narrative Review. J Fungi (Basel). 2018; 4(3). PMC: 6162658. DOI: 10.3390/jof4030097. View

14.

Ernst E, Klepser M, Pfaller M . Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob Agents Chemother. 2000; 44(4):1108-11. PMC: 89826. DOI: 10.1128/AAC.44.4.1108-1111.2000. View

15.

Alburquenque C, Bucarey S, Neira-Carrillo A, Urzua B, Hermosilla G, Tapia C . Antifungal activity of low molecular weight chitosan against clinical isolates of Candida spp. Med Mycol. 2010; 48(8):1018-23. DOI: 10.3109/13693786.2010.486412. View

16.

Senel S, Ikinci G, Kas S, Sargon M, Hincal A . Chitosan films and hydrogels of chlorhexidine gluconate for oral mucosal delivery. Int J Pharm. 1999; 193(2):197-203. DOI: 10.1016/s0378-5173(99)00334-8. View

17.

Singh K, Tiwary A, Rana V . Spray dried chitosan-EDTA superior microparticles as solid substrate for the oral delivery of amphotericin B. Int J Biol Macromol. 2013; 58:310-9. DOI: 10.1016/j.ijbiomac.2013.04.053. View

18.

Healey K, Perlin D . Fungal Resistance to Echinocandins and the MDR Phenomenon in . J Fungi (Basel). 2018; 4(3). PMC: 6162769. DOI: 10.3390/jof4030105. View

19.

Uppuluri P, Nett J, Heitman J, Andes D . Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. Antimicrob Agents Chemother. 2008; 52(3):1127-32. PMC: 2258509. DOI: 10.1128/AAC.01397-07. View

20.

Baddley J, Pappas P . Antifungal combination therapy: clinical potential. Drugs. 2005; 65(11):1461-80. DOI: 10.2165/00003495-200565110-00002. View